$1.89
▲ +$0.01
(+0.53%)
Vol 2.5M
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$350.2M
ROE
-169.3%
Margin
-936.0%
D/E
6.57
Beta
1.56
52W
$1–$3
Wall Street Consensus
14 analysts · Apr 20264
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
92.9%
Buy Rating
Price Chart
Similar Stocks
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
GLSI
Greenwich Lifesciences Inc
$291.1M
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
ORGO
Organogenesis Holdings Inc
P/E 654.1
$657.4M
Earnings
Beat rate: 60.0%
Next Report
May 11, 2026
EPS Estimate: $-0.04
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.04 | — | — |
| Dec 2025 | $-0.08 | $-0.08 | +$0.00 |
| Sep 2025 | $-0.28 | $-0.38 | $-0.10 |
| Jun 2025 | $-0.57 | $-0.58 | $-0.01 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -169.3% | -169.3% | -169.3% | -169.3% | -169.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | -936.0% | -936.0% | -936.0% | -936.0% | -936.0% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 11.98 | 0.00 | 11.98 | 11.98 | 11.98 | 6.57 |
| Current Ratio | 1.62 | 2.84 | 1.62 | 1.62 | 1.62 | 1.96 |
Key Ratios
ROA (TTM)
-126.3%
P/S (TTM)
1400.63
P/B
0.6
EPS (TTM)
$-11.78
CF/Share
$-2.62
52W High
$2.59
52W Low
$0.53
$0.53
52-Week Range
$2.59
How does PALI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
PALI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
1400.6
▲
10800%
above
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
0.6
▼
75%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
PALI profitability vs Biotechnology peers
ROE
-169.3%
▼
152%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-936.0%
▼
226%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-126.3%
▼
170%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
PALI financial health vs Biotechnology peers
D/E ratio
6.6
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
2.0
▼
56%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.6
▲
61%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
PALI fundamentals radar
PALI
Peer median
Industry
PALI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio